ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2707

Systemic Sclerosis Related Calcinosis: Patients Provide What Specialists Want to Learn

Angela Christensen1, Samara Khalique2, Sophia Cenac3, Kim Fligelstone4, Anne Mawdsley5, Tracy Frech6, Jessica K. Gordon7, Murray Baron8, Evan Busman9, Virginia D. Steen10 and Lesley Ann Saketkoo11, 1Tulane University School of Medicine, New Orleans, LA, 2Louisiana State University Health Sciences Center, New Orleans, LA, 3Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, 4Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, 5Raynaud's & Scleroderma - Care and Support UK, Cheshire, United Kingdom, 6Div of Rheumatology, University of Utah, Salt Lake City, UT, 7Rheumatology, Hospital for Special Surgery, New York, NY, 8Pavillion A, Rm 216, Jewish General Hospital, Montreal, QC, Canada, 9Atlanta Scleroderma Support Group, Atlanta, GA, 10Department of Rheumatology, Georgetown University Medical Center, Washington, DC, 11Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: calcinosis, Outcome measures, patient engagement and systemic sclerosis, PRO

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics: Determinants of Disease, Classification and Response

Session Type: Abstract Submissions (ACR)

Background/Purpose: Calcinosis is a disabling, rarely discussed manifestation of SSc for which the natural history and management is poorly understood.  Last year, the Scleroderma Clinical Trials Consortium (SCTC) established a task force to develop a calcinosis specific patient reported measure (PROM).  This investigation is the 1st phase of a multi-tiered project.

Methods: Four focus groups and individual interviews in the US and UK were recorded and transcribed verbatim.  To capture both pathophysiologic and life impact, 2 questions were asked: 1. Since developing calcinosis how has your life changed over time?  2. How has the calcinosis changed over time?  Patients were also asked to frame questions to help a physician learn if calcinosis was better, worse or the same.

Transcripts each underwent an iterative inductive process (no preconceived coding, content drives coding and analysis) by at least 5 independent analysts including at least one research team member with SSc.  Concepts were triangulated to identify a comprehensive set of meaningful concepts with occurrence quantified per participant.

Results:   Twenty-three patients (22/23 female, 19/23 white, with mean disease duration 14.8 years) were consented and interviewed.  Responses spanned broadly to include concepts of self-management strategies and recurrent hypotheses relating calcinosis development to trauma, Raynaud’s and cold exposure.  We identified discrete concepts which are described in Table 1 along with the proportion of patients declaring personal relevance.

Cold exposure and Raynaud’s were a perceived association to calcinosis severity – “when they are cold mine always open back up”.   Several described a disabling core body phenomenon involving decreased core temperature with a rapid physical decline requiring prolonged recovery potentially lasting hours – “it’s like intense – it racks your whole body”.  Calcinosis tended to present along with or soon after SSc diagnosis and remained throughout disease duration.

A majority of patients engage in strategies to extrude calcinosis with either pressure +/- soaking or at home surgical techniques.  “I actually have homemade surgical tools to get these out.”

The following anchors were consistently indicated to assess calcinosis severity:  pain level, size, frequency, number and functional impairment.

Conclusion:    Patient observations and self-management behavior provide opportunities to learn from and to preemptively educate physicians and patients.  Patients are eager for self-management guidance.  These concepts provide the groundwork for PROM development.  However, as suggested by patients, a composite of scales anchored in pain, size, frequency, number and related impairment may reasonably serve as an interim instrument for SSc calcinosis until that time. 

ACR 2014 Calcinoss 10pt Table 1.jpg


Disclosure:

A. Christensen,
None;

S. Khalique,
None;

S. Cenac,
None;

K. Fligelstone,
None;

A. Mawdsley,
None;

T. Frech,
None;

J. K. Gordon,
None;

M. Baron,
None;

E. Busman,
None;

V. D. Steen,

Actelion Pharmaceuticals US,

8,

United Therapeutics,

5,

Gilead Science,

8,

Roche Pharmaceuticals,

2,

Sanofi-Aventis Pharmaceutical,

2,

CSL Berhing,

2,

Intermune,

2,

Bayer,

5;

L. A. Saketkoo,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-sclerosis-related-calcinosis-patients-provide-what-specialists-want-to-learn/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology